Loading company…
ProteoMediX AG, based in Switzerland, develops Proclarix, a blood test for early diagnosis of prostate cancer.
Founded in 2010 and headquartered in Switzerland, ProteoMediX AG develops Proclarix, a blood test for diagnosing prostate cancer that uses the same sample as the PSA test and avoids invasive biopsies for patients with PSA levels between 2-10 ng/ml. The test is CE-IVD labeled and sold to diagnostic laboratories. Co-founders are Christian Brühlmann and Ralph Schiess. In December 2023, Blue Water Biotech agreed to acquire the company in an all-stock transaction with undisclosed terms. The latest round, led by Altos Venture, raised CHF 5.2 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in